Elif Dogan Dar

Elif Dogan Dar

Auto-generated profile, based on publicly available information

Elif Dogan Dar

University Hospital Heidelberg, Germany

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2025 in Cancer Research
Verified
Journal Article
Closed access
EMEmilija Marinkovic
Emilija Marinkovic
MCMinyi Chen
Minyi Chen
NSNadja Schubert
Nadja Schubert
EDElif Dogan Dar
Elif Dogan Dar
TPTanja Poth
Tanja Poth
ARAxel Roers
Axel Roers
Therapeutic innate immune stimulation within the tumor microenvironment can potentiate endogenous antitumor T cell immunity. Strategies for controlled activation of cGAS/STING signaling are currently under intense investigation. DNase 3’-repair exonuclease 1 (TREX1) is essential for cellular DNA disposal, which prevents autoimmunity ensuing from cGAS/STING activation by endogenous DNA. TREX1-deficient tumor cells elicit enhanced protective immunity in syngeneic models. Here, we showed that induced inactivation of the Trex1 gene in host (non-cancer) cells yields improved type I IFN- and T cell-dependent control of established TREX1-competent tumors. Host TREX1 deficiency was well tolerated and triggered selective immune cell infiltration into tumors but not into other tissues. Induced systemic loss of TREX1 in tumor-bearing mice resulted in enhanced intra-tumoral T cell proliferation and massive increase in numbers of effector and effector-like ‘exhausted’ cells, enabling complete rejection in combination with checkpoint inhibition. To conclude, systemic TREX1 inhibition is a promising approach to boost anti-tumor immunity and to overcome immune evasion mediated by cancer cell-intrinsic cGAS/STING inactivation.

1 August 2025
Verified
Other
Open access
EMEmilija Marinkovic
Emilija Marinkovic
MCMinyi Chen
Minyi Chen
NSNadja Schubert
Nadja Schubert
EDElif Dogan Dar
Elif Dogan Dar
TPTanja Poth
Tanja Poth
ARAxel Roers
Axel Roers
Therapeutic innate immune-stimulation within the tumor microenvironment can potentiate endogenous antitumor T-cell immunity. Strategies for controlled activation of cGAS/STING signaling are currently under intense investigation. DNase 3′-repair exonuclease 1 (TREX1) is essential for cellular DNA disposal, which prevents autoimmunity ensuing from cGAS/STING activation by endogenous DNA. TREX1-deficient tumor cells elicit enhanced protective immunity in syngeneic models. In this study, we showed that induced inactivation of the Trex1 gene in host (noncancer) cells yields improved type I IFN- and T-cell–dependent control of established TREX1-competent tumors. Host TREX1 deficiency was well tolerated and triggered selective immune cell infiltration into tumors but not into other tissues. Induced systemic loss of TREX1 in tumor-bearing mice resulted in enhanced intratumoral T-cell proliferation and massive increase in numbers of effector and effector-like “exhausted” cells, enabling complete rejection in combination with checkpoint inhibition. To conclude, systemic TREX1 inhibition is a promising approach to boost antitumor immunity and to overcome immune evasion mediated by cancer cell–intrinsic cGAS/STING inactivation.Significance:Selective inflammation of tumor tissue and efficient tumor immune control by systemically induced loss of TREX1 support the potential efficacy and therapeutic window for treating cancer with TREX1 inhibitors.

1 August 2025
Verified
Other
Open access
EMEmilija Marinkovic
Emilija Marinkovic
MCMinyi Chen
Minyi Chen
NSNadja Schubert
Nadja Schubert
EDElif Dogan Dar
Elif Dogan Dar
TPTanja Poth
Tanja Poth
ARAxel Roers
Axel Roers
Figure S2 shows gating of immune cell populations in tumor tissue as well as quantification of immune cells in tumor, tumor-draining lymph node and spleen.

1 August 2025
Verified
Other
Open access
EMEmilija Marinkovic
Emilija Marinkovic
MCMinyi Chen
Minyi Chen
NSNadja Schubert
Nadja Schubert
EDElif Dogan Dar
Elif Dogan Dar
TPTanja Poth
Tanja Poth
ARAxel Roers
Axel Roers
Figure S6 shows the inflammatory switch of the intra-tumoral myeloid compartment in TREX1 iKO hosts.

1 August 2025
Verified
Other
Open access
EMEmilija Marinkovic
Emilija Marinkovic
MCMinyi Chen
Minyi Chen
NSNadja Schubert
Nadja Schubert
EDElif Dogan Dar
Elif Dogan Dar
TPTanja Poth
Tanja Poth
ARAxel Roers
Axel Roers
Figure S1 shows efficiency of induced TREX1 deletion and how induced loss of TREX1 impacts growth of MB49 tumors.

1 August 2025
Verified
Other
Open access
EMEmilija Marinkovic
Emilija Marinkovic
MCMinyi Chen
Minyi Chen
NSNadja Schubert
Nadja Schubert
EDElif Dogan Dar
Elif Dogan Dar
TPTanja Poth
Tanja Poth
ARAxel Roers
Axel Roers
Figure S8 shows single cell data on the invigorated intra-tumoral CD8 T cell response upon loss of TREX1 in the host.